Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
ReplyCorrespondence

Dr. Khan, Dr. Hanley, and Dr. Peters reply

ALIYA KHAN, DAVID A. HANLEY and EDMUND PETERS
The Journal of Rheumatology February 2009, 36 (2) 453; DOI: https://doi.org/10.3899/jrheum.080808
ALIYA KHAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: avkhan@aol.com
DAVID A. HANLEY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EDMUND PETERS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We thank Dr. Fung and Dr. Campisi and colleagues for their responses.

The points raised by Dr. Fung are of value and have been emphasized in the editorial recently published in The Journal1. His other comments pertaining to the need to adjudicate reported cases have also been stressed in our systematic review on bisphosphonate (BP) associated osteonecrosis of the jaw (ONJ)2. The systematic review provides the incidence data in patient-years to ensure that these data are not misinterpreted. BP are of great benefit in the management of osteoporosis and other metabolic bone disorders, and if utilized appropriately according to the recently published guidelines3 are safe and effective agents. Data in the Canadian survey will shed more light on this issue, as pointed out by Dr. Fung, and are eagerly awaited.

In response to the issues presented by Dr. Campisi and colleagues:

  1. We are not claiming that there is no association between low-dose BP use in the osteoporosis patient population and ONJ, but rather that the true incidence is low enough to raise doubts that it differs from conditions occurring in the general population that can easily be classified as ONJ. It is our understanding that the cases reported to Merck were unadjudicated, and undoubtedly included dental conditions other than ONJ. The quality of published reports on BP associated ONJ have been variable and it was necessary to make decisions regarding the emphasis the various papers should be accorded. In particular, with respect to the oral BP, we felt it was premature to accept purported incidence figures. In this regard, we do not believe that cases derived from class action lawsuits, obtained by lawyers actively canvassing for clients, should be part of a scientific discussion. Physicians should be cautioned against using litigation proceedings as an indicator of the true frequency of a condition.

  2. Campisi, et al are confusing our observation that many patients have been frightened into stopping their osteoporosis therapies by sensational news reports with our conservative recommendations for stopping BP use prior to invasive dental procedures. Although we have no evidence that discontinuation of BP prior to dental procedures offers any protection against ONJ, because of the unlikely harm in stopping the BP for several months, we do recommend interruption of BP treatment prior to invasive dental procedures. The use of “drug holidays” requires further study and has been recognized in our repor as a knowledge gap.

  3. Canadian dental recommendations include regular assessments on a 6-monthly basis for all Canadians. If a patient is receiving “appropriate dental care” and has “good oral hygiene,” we fail to see the benefit provided by another dental examination in a patient with osteoporosis being prescribed low-dose BP therapy. It is not clear if Campisi, et al are seriously suggesting that a patient with osteoporosis should be denied treatment with our most effective medications if they have evidence of mild periodontal disease. Our recommendations for the oncology patient, however, did include a thorough dental examination prior to initiating high-dose BP therapy.

  4. We agree that there are multiple factors that can predispose to ONJ. However, ONJ does occur spontaneously without exposure to BP. “Lingual mandibular sequestration” occurs in healthy adults, yet resembles mild forms of BP associated ONJ. In light of these considerations, characterizing every patient who has used oral BP and also develops ONJ as an example of BP associated ONJ does not seem reasonable. The concern is that this preemptively assigns an etiologic implication to the use of BP and may lead to an obvious selection bias in studies that should be attempting to assess the contribution of the drug to the ONJ problem. There is clearly an urgent need for controlled studies.

  5. Imaging technologies can help characterize ONJ and these will undoubtedly continue to improve, along with other methods. We agree that there is a role for radiologic investigation in ONJ, and recommended this in the assessment of oncology patients receiving high-dose intravenous BP.

The role of imaging is described in detail in our systematic review2. It is important to note, however, that the clinical presentation remains the most important element in diagnosis and the American Association of Oral and Maxillofacial Surgeons, in their 2007 position paper4, exclusively use clinical criteria to define these cases.

REFERENCES

  1. 1.↵
    1. Khan AA
    . Osteonecrosis of the jaw: new developments in an old disease [editorial]. J Rheumatol 2008;35:547–9.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Khan AA,
    2. Sándor GKB,
    3. Dore E,
    4. et al
    . Bisphosphonate associated osteonecrosis of the jaw [review]. J Rheumatol 2009;36: [in press].
  3. 3.↵
    1. Khan AA,
    2. Sándor GK,
    3. Dore E,
    4. et al
    . Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:1391–7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws
    . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369–76.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 2
1 Feb 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dr. Khan, Dr. Hanley, and Dr. Peters reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dr. Khan, Dr. Hanley, and Dr. Peters reply
ALIYA KHAN, DAVID A. HANLEY, EDMUND PETERS
The Journal of Rheumatology Feb 2009, 36 (2) 453; DOI: 10.3899/jrheum.080808

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dr. Khan, Dr. Hanley, and Dr. Peters reply
ALIYA KHAN, DAVID A. HANLEY, EDMUND PETERS
The Journal of Rheumatology Feb 2009, 36 (2) 453; DOI: 10.3899/jrheum.080808
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • To the Editor:
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Dr. Kitajima et al reply
  • Dr. Putman et al reply
  • Drs. Chung and McMahan reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire